The Influence of Sarcopenia on High-Risk Neuroblastoma

Naonori Kawakubo, Yoshiaki Kinoshita, Ryota Sozaki, Yuhki Koga, Utako Oba, Shoichi Ohga, Tomoaki Taguchi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Sarcopenia is a syndrome that is defined by the loss of skeletal muscle mass, quality, and strength. In adult patients with malignancies, the presence of sarcopenia is known to be correlated with a poor prognosis; however, there have been no reports on the influence of sarcopenia on malignant tumors in pediatric patients. In the present study, we investigated whether or not sarcopenia affects the prognosis of high-risk neuroblastoma. Materials and methods: Thirteen patients with high-risk neuroblastoma who were treated according to the standard protocol at our hospital from 2007 to 2016 were divided into a progression-free survival group (n = 8) and a relapse/death group (n = 5). The rate of change in sarcopenia was calculated by comparing the psoas muscle area (PMA) of the L3-level lumbar spine on computed tomography before and after treatment with the standard protocol. The rate of change in the PMA, Kaup index, and serum albumin level were compared. Furthermore, we determined the cutoff rate of change in the PMA and compared the overall and progression-free survival. Results: The rates of change in the PMA were 1.24 and 0.84 in the progression-free survival and relapse/death groups, respectively (P = 0.0472). There were no significant differences in the rates of change in the Kaup index or the serum albumin level of the two groups. The patients whose rate of change in the PMA was >1.00 showed a prolonged overall (P = 0.0078) and progression-free survival (P = 0.006). Conclusions: A decrease in the skeletal muscle mass was suggested to be a significant prognostic factor for high-risk neuroblastoma.

Original languageEnglish
Pages (from-to)101-105
Number of pages5
JournalJournal of Surgical Research
Volume236
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Psoas Muscles
Sarcopenia
Neuroblastoma
Disease-Free Survival
Serum Albumin
Skeletal Muscle
Recurrence
Neoplasms
Spine
Tomography
Pediatrics

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

The Influence of Sarcopenia on High-Risk Neuroblastoma. / Kawakubo, Naonori; Kinoshita, Yoshiaki; Sozaki, Ryota; Koga, Yuhki; Oba, Utako; Ohga, Shoichi; Taguchi, Tomoaki.

In: Journal of Surgical Research, Vol. 236, 01.04.2019, p. 101-105.

Research output: Contribution to journalArticle

Kawakubo, Naonori ; Kinoshita, Yoshiaki ; Sozaki, Ryota ; Koga, Yuhki ; Oba, Utako ; Ohga, Shoichi ; Taguchi, Tomoaki. / The Influence of Sarcopenia on High-Risk Neuroblastoma. In: Journal of Surgical Research. 2019 ; Vol. 236. pp. 101-105.
@article{0f4618d3da444ecb95be7a547f4f9946,
title = "The Influence of Sarcopenia on High-Risk Neuroblastoma",
abstract = "Purpose: Sarcopenia is a syndrome that is defined by the loss of skeletal muscle mass, quality, and strength. In adult patients with malignancies, the presence of sarcopenia is known to be correlated with a poor prognosis; however, there have been no reports on the influence of sarcopenia on malignant tumors in pediatric patients. In the present study, we investigated whether or not sarcopenia affects the prognosis of high-risk neuroblastoma. Materials and methods: Thirteen patients with high-risk neuroblastoma who were treated according to the standard protocol at our hospital from 2007 to 2016 were divided into a progression-free survival group (n = 8) and a relapse/death group (n = 5). The rate of change in sarcopenia was calculated by comparing the psoas muscle area (PMA) of the L3-level lumbar spine on computed tomography before and after treatment with the standard protocol. The rate of change in the PMA, Kaup index, and serum albumin level were compared. Furthermore, we determined the cutoff rate of change in the PMA and compared the overall and progression-free survival. Results: The rates of change in the PMA were 1.24 and 0.84 in the progression-free survival and relapse/death groups, respectively (P = 0.0472). There were no significant differences in the rates of change in the Kaup index or the serum albumin level of the two groups. The patients whose rate of change in the PMA was >1.00 showed a prolonged overall (P = 0.0078) and progression-free survival (P = 0.006). Conclusions: A decrease in the skeletal muscle mass was suggested to be a significant prognostic factor for high-risk neuroblastoma.",
author = "Naonori Kawakubo and Yoshiaki Kinoshita and Ryota Sozaki and Yuhki Koga and Utako Oba and Shoichi Ohga and Tomoaki Taguchi",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.jss.2018.10.048",
language = "English",
volume = "236",
pages = "101--105",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The Influence of Sarcopenia on High-Risk Neuroblastoma

AU - Kawakubo, Naonori

AU - Kinoshita, Yoshiaki

AU - Sozaki, Ryota

AU - Koga, Yuhki

AU - Oba, Utako

AU - Ohga, Shoichi

AU - Taguchi, Tomoaki

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose: Sarcopenia is a syndrome that is defined by the loss of skeletal muscle mass, quality, and strength. In adult patients with malignancies, the presence of sarcopenia is known to be correlated with a poor prognosis; however, there have been no reports on the influence of sarcopenia on malignant tumors in pediatric patients. In the present study, we investigated whether or not sarcopenia affects the prognosis of high-risk neuroblastoma. Materials and methods: Thirteen patients with high-risk neuroblastoma who were treated according to the standard protocol at our hospital from 2007 to 2016 were divided into a progression-free survival group (n = 8) and a relapse/death group (n = 5). The rate of change in sarcopenia was calculated by comparing the psoas muscle area (PMA) of the L3-level lumbar spine on computed tomography before and after treatment with the standard protocol. The rate of change in the PMA, Kaup index, and serum albumin level were compared. Furthermore, we determined the cutoff rate of change in the PMA and compared the overall and progression-free survival. Results: The rates of change in the PMA were 1.24 and 0.84 in the progression-free survival and relapse/death groups, respectively (P = 0.0472). There were no significant differences in the rates of change in the Kaup index or the serum albumin level of the two groups. The patients whose rate of change in the PMA was >1.00 showed a prolonged overall (P = 0.0078) and progression-free survival (P = 0.006). Conclusions: A decrease in the skeletal muscle mass was suggested to be a significant prognostic factor for high-risk neuroblastoma.

AB - Purpose: Sarcopenia is a syndrome that is defined by the loss of skeletal muscle mass, quality, and strength. In adult patients with malignancies, the presence of sarcopenia is known to be correlated with a poor prognosis; however, there have been no reports on the influence of sarcopenia on malignant tumors in pediatric patients. In the present study, we investigated whether or not sarcopenia affects the prognosis of high-risk neuroblastoma. Materials and methods: Thirteen patients with high-risk neuroblastoma who were treated according to the standard protocol at our hospital from 2007 to 2016 were divided into a progression-free survival group (n = 8) and a relapse/death group (n = 5). The rate of change in sarcopenia was calculated by comparing the psoas muscle area (PMA) of the L3-level lumbar spine on computed tomography before and after treatment with the standard protocol. The rate of change in the PMA, Kaup index, and serum albumin level were compared. Furthermore, we determined the cutoff rate of change in the PMA and compared the overall and progression-free survival. Results: The rates of change in the PMA were 1.24 and 0.84 in the progression-free survival and relapse/death groups, respectively (P = 0.0472). There were no significant differences in the rates of change in the Kaup index or the serum albumin level of the two groups. The patients whose rate of change in the PMA was >1.00 showed a prolonged overall (P = 0.0078) and progression-free survival (P = 0.006). Conclusions: A decrease in the skeletal muscle mass was suggested to be a significant prognostic factor for high-risk neuroblastoma.

UR - http://www.scopus.com/inward/record.url?scp=85057582475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057582475&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2018.10.048

DO - 10.1016/j.jss.2018.10.048

M3 - Article

VL - 236

SP - 101

EP - 105

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

ER -